ARST1321: Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754, IND# 118613)

ID Number 80-0066-01321

Principal Investigator(s)
Birte Wistinghausen

Department(s) or Division(s)
Hematology and Medical Oncology


You are being asked to take part in this research study because you have a type of cancer called non-rhabdomyosarcoma soft tissue sarcoma (NRSTS).  This study is for people with intermediate or high risk NRSTS that cannot be removed by surgery at the time of diagnosis.  The term risk refers to the chance of the cancer coming back after treatment.  You are being given this informed consent form because you have decided to proceed with chemotherapy and radiation treatment combined with surgery based on your discussion with your treating physician.  You are in the chemotherapy group Part 1 of this study.

Contact Information
Dr Birte Wistinghausen
(212) 824-7309

Recruiting Patients: Yes